BridgeMD
New treatment option for Multiple System Atrophy
Official title A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
ClinicalTrials.gov ID: NCT06868628
What this study is testing
What is Foralumab Nasal?
Foralumab Nasal is an investigational medicine, being studied as a potential treatment for multiple system atrophy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 85
You may be able to join if
- people with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic...
- Age 30 to 85 years, at the time of signing the informed consent.
- Stable dopaminergic treatment for at least 4 weeks before enrollment.
- Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L.
- Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula.
You likely can't join if
- Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis.
- Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study.
- Individuals with claustrophobia who cannot tolerate the study procedures
- Non-MRI-compatible implanted devices.
- Low-affinity binders for translocator protein (TSPO) PET ligands.
- Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment).
See the full eligibility criteria
- people with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria.
- Age 30 to 85 years, at the time of signing the informed consent.
- Stable dopaminergic treatment for at least 4 weeks before enrollment.
- Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L.
- Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula.
- Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN.
- QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening.
- Negative urine pregnancy test within 7 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not...
- Patients whose immunizations are fully up to date at the Screening, according to the assessment of their primary care physician and neurologist.
- Ability to provide written informed consent.
- Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis.
- Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study.
- Individuals with claustrophobia who cannot tolerate the study procedures
- Non-MRI-compatible implanted devices.
- Low-affinity binders for translocator protein (TSPO) PET ligands.
- Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment).
- Individuals with significant cognitive impairment (i.e., MoCA score less than or equal to 20).
- Brain MRI indicative of significant abnormalities that interfere with PET-MRI co-registration (i.e., large prior hemorrhage or multiple infarcts).
- Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or...
- Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are...
- Patients who test positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or positive Epstein-Barr virus (EBV) IgM at the Screening Visit.
- Past medical history of a hematologic or solid malignancy.
- Treatment with chronic immunosuppressives such as interferon, glatiramer acetate, fingolimod, Siponimod, dimethyl fumarate, or natalizumab within the past 90 days.
- Inability to tolerate nasally administered medications.
- Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days, or anticipated need during the study.
- Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 8 months.
- Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's Syndrome, asthma, or type 1 diabetes.
- Neutropenia or an absolute neutrophil count of \< 1,000 cells/mL or other indicators of severe immunosuppression.
- Severe lymphopenia or an absolute lymphocyte count of \< 500 cells/mL
- Patients with a history of gadolinium allergy.
- A recent clinically significant active infection requiring treatment with antibiotics or other anti-infective agents within the past 15 days.
- Any other medical or surgical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results.
- Unable or unwilling to comply with protocol requirements.
- Active COVID-19 disease.
- COVID-19 vaccine within past 10 days or any other vaccine within past 7 days (at dosing).
The study team makes the final eligibility decision.
Where it's taking place
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boston, Massachusetts, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.